STAT+: Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug
Amid a firestorm of controversy around its decision to charge $56,000 a year for an Alzheimer’s disease treatment whose benefits are disputed, Biogen defended its decision on Tuesday, pointing to life-saving cancer therapies that can cost nearly three times as much.
“We consider this to be a really responsible price, and we consider this to be a price that’s sustainable for the system,” CEO Michel Vounatsos said on a triumphant conference call with Wall Street analysts.
